MA30660B1 - Procedes de production de conjugues du facteurs de croissance i de type insuline (igf-i) et de polyethyleneglycol. - Google Patents

Procedes de production de conjugues du facteurs de croissance i de type insuline (igf-i) et de polyethyleneglycol.

Info

Publication number
MA30660B1
MA30660B1 MA31660A MA31660A MA30660B1 MA 30660 B1 MA30660 B1 MA 30660B1 MA 31660 A MA31660 A MA 31660A MA 31660 A MA31660 A MA 31660A MA 30660 B1 MA30660 B1 MA 30660B1
Authority
MA
Morocco
Prior art keywords
pro
igf
variant
pegylated
polyethylene glycol
Prior art date
Application number
MA31660A
Other languages
English (en)
Inventor
Stephan Fischer
Friederike Hesse
Hendrik Knoetgen
Kurt Lang
Friedrich Metzger
Joerg Thomas Regula
Christian Schantz
Andreas Schaubmar
Hans Joachim Schoenfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37667695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30660(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30660B1 publication Critical patent/MA30660B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procédé de production de conjugués du facteur de croissance analogue à l'insuline 1 et de polyéthylèneglycol Procédé de production d'un IGF-I ou d'une variante d'IGF-1 pégylé(e) sur la lysine, ladite variante comprenant un ou deux aminoacides choisis dans le groupe constitué par la lysine 27, 65 et/ou 68 remplacés indépendamment par un autre aminoacide polaire, caractérisé en ce que l'on cultive une cellule hôte procaryote comprenant un vecteur d'expression contenant un acide nucléique codant pour une protéine de fusion comprenant ledit IGF-I ou ladite variante d'IGF-I lié(e) en position N-terminale à l'extrémité C-terminale d'un propeptide, ledit propeptide se terminant à l'extrémité C-terminale par les aminoacides -Y-Pro, où Y est choisi dans le groupe constitué par Pro, Pro-Ala, Pro-Gly, Pro-Thr, Ala-Pro, Gly-Pro, Thr-Pro, Arg-Pro ou Pro-Arg-Pro, on récupère ladite protéine de fusion et on la soumet à une pégylation, on coupe ladite protéine de fusion pégylée avec une IgA-protéase, et on récupère ledit IGF-I ou ladite variante d'IGF-I pégylé(e). L'IGF-I ou la variante d'IGF-I pégylé(e) est utile pour le traitement de troubles neurodégénératifs comme la maladie d'Alzheimer.
MA31660A 2006-08-31 2009-02-25 Procedes de production de conjugues du facteurs de croissance i de type insuline (igf-i) et de polyethyleneglycol. MA30660B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06018170 2006-08-31

Publications (1)

Publication Number Publication Date
MA30660B1 true MA30660B1 (fr) 2009-08-03

Family

ID=37667695

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31660A MA30660B1 (fr) 2006-08-31 2009-02-25 Procedes de production de conjugues du facteurs de croissance i de type insuline (igf-i) et de polyethyleneglycol.

Country Status (21)

Country Link
US (4) US7625996B2 (fr)
EP (1) EP2059261B1 (fr)
JP (1) JP5184532B2 (fr)
KR (1) KR101106931B1 (fr)
CN (1) CN101511390B (fr)
AR (1) AR062575A1 (fr)
AU (1) AU2007291502B2 (fr)
BR (1) BRPI0715943A2 (fr)
CA (1) CA2662062C (fr)
CL (1) CL2007002502A1 (fr)
CO (1) CO6251278A2 (fr)
CR (1) CR10591A (fr)
ES (1) ES2397660T3 (fr)
IL (1) IL196736A (fr)
MA (1) MA30660B1 (fr)
MX (1) MX2009002011A (fr)
NO (1) NO20090451L (fr)
PE (1) PE20080912A1 (fr)
RU (1) RU2009106118A (fr)
TW (1) TW200819468A (fr)
WO (1) WO2008025528A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674113A1 (fr) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugués de l'IGF-1 et du poly(éthylène glycol)
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
EP2059530B1 (fr) 2006-08-31 2012-08-29 F.Hoffmann-La Roche Ag Procede de production du facteur de croissance i de type insuline (igf-i)
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
WO2009099763A1 (fr) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Promédicaments peptidiques à base d’esters
WO2009121759A2 (fr) * 2008-04-03 2009-10-08 F. Hoffmann-La Roche Ag Utilisation de variants de igf-i pegylés pour traiter des troubles neuromusculaires
AU2009335713A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation YL-based insulin-like growth factors exhibiting high activity at the insulin receptor
US8697632B2 (en) 2008-12-19 2014-04-15 Indiana University Research And Technology Corporation Amide based insulin prodrugs
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
BR112012019992A2 (pt) * 2010-02-11 2020-08-18 F. Hoffmann-La Roche Ag. conjugados de igf-i poli (etileno glicol)
CA2802485C (fr) 2010-06-16 2019-09-17 Indiana University Research And Technology Corporation Agonistes de l'insuline a une seule chaine tres actifs au niveau du recepteur a l'insuline
US8946147B2 (en) 2010-06-24 2015-02-03 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
GB201012784D0 (en) 2010-07-29 2010-09-15 Ucb Pharma Sa Method
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
WO2014052451A2 (fr) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Dimères analogues de l'insuline
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
WO2014205617A1 (fr) * 2013-06-24 2014-12-31 Shandong University Peptide marqué au lanthanide et utilisation de celui-ci
EP3052123A1 (fr) 2013-10-02 2016-08-10 Novartis Ag Mimétique du facteur de croissance semblable à l'insuline destiné à être utilisé en thérapie
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
EP3206710B1 (fr) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Conjugués d'insuline-incrétines
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
WO2017147298A1 (fr) 2016-02-23 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Procédés à base de peptides pour traiter une lésion neurologique
EP3911668A1 (fr) 2019-01-18 2021-11-24 The Regents of the University of Colorado, a body corporate Peptides antimicrobiens alpha-hélicoïdaux amphipathiques pour le traitement d'infections par des agents pathogènes à gram-négatif

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE95236T1 (de) 1983-04-25 1993-10-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren.
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US6235488B1 (en) 1988-09-29 2001-05-22 Agilent Technologies, Inc. Surface preparation for chemical-specific binding
EP0400472B1 (fr) 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Procédé pour la préparation de dérivés de polyéthylène glycol et protéine modifiée.
US6723699B1 (en) * 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
DE3924705A1 (de) 1989-07-26 1991-01-31 Boehringer Mannheim Gmbh Heterobifunktionelle verbindungen
US5158875A (en) * 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5861373A (en) 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
DK0597033T3 (da) 1991-08-01 1997-06-02 Genentech Inc IGF-1 til forbedring af den neurale tilstand
AU6048294A (en) 1992-11-25 1994-06-22 Amgen Boulder Inc. Modified insulin-like growth factors
EP0756494A1 (fr) 1994-05-24 1997-02-05 Amgen Boulder Inc. Facteurs de croissance proches de l'insuline modifies
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
WO1998035026A1 (fr) 1997-02-06 1998-08-13 Novo Nordisk A/S Conjugats polypeptide-polymere a groupes de fixation ajoutes et/ou retires
US20030204864A1 (en) * 2001-02-28 2003-10-30 Henry Daniell Pharmaceutical proteins, human therapeutics, human serum albumin, insulin, native cholera toxic b submitted on transgenic plastids
US6767892B1 (en) 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
US7067485B2 (en) 1997-11-07 2006-06-27 Chiron Corporation IGF-I composition and its use
US6248546B1 (en) 1998-03-09 2001-06-19 Diagnostic Systems Laboratories, Inc. Assay of IGFBP complex
WO1999055362A1 (fr) 1998-04-29 1999-11-04 Genentech, Inc. Formulations de igf-i sechees par pulverisation
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
EP0972838B1 (fr) 1998-07-15 2004-09-15 Roche Diagnostics GmbH Système de sélection par complémentation d' une auxotrophie en absence d'antibiotique chez E. coli
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
WO2000040612A1 (fr) 1999-01-06 2000-07-13 Genentech, Inc. Variants mutants du facteur de croissance i semblable a l'insuline (igf)
ATE251466T1 (de) 1999-04-08 2003-10-15 Genentech Inc Zusammensetzung auf basis gegensätzlich geladener polypeptide
US6596849B1 (en) 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
WO2001087323A2 (fr) * 2000-05-16 2001-11-22 Genentech, Inc. Procede de traitement des lesions du cartilage
WO2001088149A1 (fr) * 2000-05-16 2001-11-22 Center For Advanced Science And Technology Incubation, Ltd. Polypeptides de clivage de repetitions telomeriques
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
EP1286700A2 (fr) 2000-06-01 2003-03-05 Universite Catholique De Louvain Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers
WO2002032449A2 (fr) 2000-10-13 2002-04-25 Chiron Corporation Procede de traitement d'accidents ischemiques affectant le systeme nerveux central
KR20080085082A (ko) 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 융합 단백질
US20030017504A1 (en) 2001-05-21 2003-01-23 Shearwater Corporation Antibodies specific for poly(ethylene glycol)
JP2006519170A (ja) * 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
EP1674113A1 (fr) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugués de l'IGF-1 et du poly(éthylène glycol)
HUE027645T2 (en) 2005-01-07 2016-10-28 Regeneron Pharma IGF-1 fusion proteins and therapeutic applications
BRPI0709843A2 (pt) * 2006-03-28 2011-07-26 Biogen Idec Inc anticorpos de anti-igf-1r e usos dos mesmos
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
WO2009121759A2 (fr) 2008-04-03 2009-10-08 F. Hoffmann-La Roche Ag Utilisation de variants de igf-i pegylés pour traiter des troubles neuromusculaires

Also Published As

Publication number Publication date
CN101511390B (zh) 2013-04-24
US20100035817A1 (en) 2010-02-11
AR062575A1 (es) 2008-11-19
EP2059261A1 (fr) 2009-05-20
WO2008025528A1 (fr) 2008-03-06
TW200819468A (en) 2008-05-01
JP2010501192A (ja) 2010-01-21
IL196736A0 (en) 2009-11-18
US20100210547A1 (en) 2010-08-19
JP5184532B2 (ja) 2013-04-17
KR20090046875A (ko) 2009-05-11
MX2009002011A (es) 2009-03-05
CL2007002502A1 (es) 2008-05-30
RU2009106118A (ru) 2010-10-10
AU2007291502A1 (en) 2008-03-06
ES2397660T3 (es) 2013-03-08
AU2007291502B2 (en) 2012-05-31
PE20080912A1 (es) 2008-07-19
CR10591A (es) 2009-04-03
KR101106931B1 (ko) 2012-01-25
US8476232B2 (en) 2013-07-02
US7625996B2 (en) 2009-12-01
US20130065831A1 (en) 2013-03-14
CO6251278A2 (es) 2011-02-21
IL196736A (en) 2013-10-31
NO20090451L (no) 2009-02-26
EP2059261B1 (fr) 2012-10-24
US20080119409A1 (en) 2008-05-22
CN101511390A (zh) 2009-08-19
BRPI0715943A2 (pt) 2013-07-30
CA2662062C (fr) 2015-06-23
CA2662062A1 (fr) 2008-03-06

Similar Documents

Publication Publication Date Title
MA30660B1 (fr) Procedes de production de conjugues du facteurs de croissance i de type insuline (igf-i) et de polyethyleneglycol.
WO2008025527A8 (fr) Procédé de production du facteur de croissance 1 analogue à l'insuline
CN101384623B (zh) 白蛋白与治疗剂的预成型偶联物的制备方法
Nilsson et al. Fusion proteins in biotechnology and structural biology
HRP20150326T1 (hr) Stabilizirani polipeptidi faktora rasta nalik na inzulin
AU765206B2 (en) Process for producing peptide with the use of accessory peptide
RU2018119141A (ru) Слитые с fgf21 белки длительного действия и содержащая их фармацевтическая композиция
EP1392717A4 (fr) Systeme d'expression de proteine sumo a scission rapide pour proteines difficiles a exprimer
US10000544B2 (en) Process for production of insulin and insulin analogues
JP7246323B2 (ja) Ｓ２又はｓ２’ポケット中の突然変異を有するサブチリシンバリアント
KR100989413B1 (ko) 새로운 융합파트너를 이용한 재조합 단백질의 제조방법
Buchanan et al. Novel therapeutic proteins and peptides
JP2021511785A (ja) 組換えポリペプチド生産用ｎ末端融合パートナーおよびこれを用いた組換えポリペプチドの生産方法
CA2198966A1 (fr) Methode de clivage d'une proteine chimere a l'aide d'une enzyme de traitement
EP2839010B1 (fr) Procédé de production d'un peptide recombinant
WO2017222369A1 (fr) Couplage enzymatique de (oligo)peptides à la chaîne b d'un ligand du récepteur de l'insuline
US20060035316A1 (en) Plasmids expressing human insulin and the preparation method for human insuling thereby
WO2007056524A3 (fr) Chimeres st3gal-1/st6galnac-1
Charlton Improved production of biopharmaceuticals by site-specific cleavage of fusion proteins expressed in Escherichia coli.
KR20100001632A (ko) 대장균에서 활성형 인간 인터루킨-6의 생산 및 정제방법